Ophthalmic company Notal Vision Ltd reported on Monday the receipt of the US Food and Drug Administration (FDA) 'Breakthrough Device' designation for the Notal Vision Home-based Optical Coherence Tomography (OCT) System for the automated testing in exudative age-related macular degeneration (eAMD) patients.
The company said the Notal Home OCT is a patient-friendly light-weight device designed for technician-free operation by eAMD patients from the comfort of their home. Once a patient completes the test, a proprietary machine-learning algorithm, the Notal OCT Analyzer (NOA), performs an automated analysis. If retina fluid is detected, a report is generated by NOA which is then conveyed to the treating physician by the Notal Vision Diagnostic Clinic.
Following a report, patients may be brought to the office for evaluation and treatment at the physician's discretion. The Notal Home OCT has the potential to truly individualise retinal disease management, added the company.
In addition, the company plans to launch the Notal Vision Home OCT System to the market in 2020.
Oncopeptides to apply for melflufen's accelerated approval with the US FDA for multiple myeloma
Stryker wins US FDA premarket approval for Neuroform Atlas Stent System to treat brain aneurysms
Infant Bacterial Therapeutics announces agreement by US FDA on design of phase III study
Ambu and Cook Medical enter into agreement on distribution of disposable duodenoscopes in the US
Inteliquet executes Cooperative R&D Agreement with the National Cancer Institute